16900-57-5
Chemical Structure
DL-Propargylglycine hydrochloride
- CAS No.: 16900-57-5
- Formula:C5H8ClNO2
- Molecular Weight:149.58
IUPAC Name: 2-aminopent-4-ynoic acid hydrochloride
InChIKey: UAMBUICGODABQY-UHFFFAOYSA-N
SMILES: C#CCC(N)C(O)=O.[H]Cl
Biological Activity: DL-Propargylglycine hydrochloride is an irreversible and selective CSE inhibitor that blocks the biosynthesis of endogenous hydrogen sulfide. DL-Propargylglycine hydrochloride induces ROS and TGF-β1 expression. DL-Propargylglycine hydrochloride downregulates carotid ACE2 and Ang-(1-7), and elevates Ang II. DL-Propargylglycine hydrochloride upregulates ICAM-1/LFA-1, exacerbating Aspirin (HY-14654)-induced gastric mucosal injury. DL-Propargylglycine hydrochloride is used in research on diabetes-induced liver injury, diabetic nephropathy, atherosclerosis, gastric mucosal injury, hemorrhagic shock, and Streptococcus agalactiae infection[1][2][3][4][5][6][7][8][9].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DL-Propargylglycine hydrochloride | DL-Propargylglycine hydrochloride is an irreversible and selective CSE inhibitor that blocks the biosynthesis of endogenous hydrogen sulfide. DL-Propargylglycine hydrochloride induces ROS and TGF-β1 expression. DL-Propargylglycine hydrochloride downregulates carotid ACE2 and Ang-(1-7), and elevates Ang II. DL-Propargylglycine hydrochloride upregulates ICAM-1/LFA-1, exacerbating Aspirin (HY-14654)-induced gastric mucosal injury. DL-Propargylglycine hydrochloride is used in research on diabetes-induced liver injury, diabetic nephropathy, atherosclerosis, gastric mucosal injury, hemorrhagic shock, and Streptococcus agalactiae infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Dugbartey GJ, et al. Targeting hepatic sulfane sulfur/hydrogen sulfide signaling pathway with α-lipoic acid to prevent diabetes-induced liver injury via upregulating hepatic CSE/3-MST expression. Diabetology & metabolic syndrome. 2022 Oct 13;14(1):148.
- [2]. Yuan P, et al. Rescue of mesangial cells from high glucose-induced over-proliferation and extracellular matrix secretion by hydrogen sulfide. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2011 Jul;26(7):2119-26.
- [3]. Lin Y, et al. Hydrogen Sulfide Attenuates Atherosclerosis in a Partially Ligated Carotid Artery Mouse model via Regulating Angiotensin Converting Enzyme 2 Expression. Frontiers in physiology. 2017;8:782.
- [4]. Muslemyar QS, et al. Melatonin and L‐cysteine desulfhydrase: unraveling hydrogen sulfide signaling for drought tolerance in bread wheat (Triticum aestivum). Food and Energy Security. 2025 May;14(3):e70103.
- [5]. Fiorucci S, et al. Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology. 2005 Oct;129(4):1210-24.
- [6]. Xu Y, et al. Statins upregulate cystathionine γ-lyase transcription and H2S generation via activating Akt signaling in macrophage. Pharmacological research. 2014 Sep;87:18-25.
- [7]. Mok YY, et al. Role of hydrogen sulphide in haemorrhagic shock in the rat: protective effect of inhibitors of hydrogen sulphide biosynthesis. British journal of pharmacology. 2004 Dec;143(7):881-9.
- [8]. Chen XW, et al. DL-propargylglycine reverses beta-lactam resistance in Streptococcus agalactiae. Microbiological research. 2026 Jan;302:128350. [Content Brief]
- [9]. Getsy PM, et al. The cystathionine-γ-lyase inhibitor DL-propargylglycine augments the ability of L-cysteine ethyl ester to overcome the adverse effects of morphine on breathing. American journal of physiology. Lung cellular and molecular physiology. 2025 Jun 01;328(6):L809-L825.
